Oculis Holding AG
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Large accelerated filer
State of Incorporation
Switzerland
Business Address
BAHNHOFSTRASSE 7, ZUG, V8, 6300
Mailing Address
BAHNHOFSTRASSE 7, ZUG, V8, 6300
Phone
617-937-2423
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 4, 2026 | View on SEC |
| 20-F Foreign company annual report | March 4, 2026 | View on SEC |
| 6-K Foreign company current report | March 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 6-K Foreign company current report | November 10, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 31, 2025 | View on SEC |
| 6-K Foreign company current report | October 31, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 31, 2025 | View on SEC |
| 6-K Foreign company current report | October 29, 2025 | View on SEC |
Annual Reports
20-F
March 4, 2026
- Lead drug candidate OCS-01 is in Phase 3 clinical trials for DME and DED, showing positive progress in the OPTIMIZE trial for DME.
- Two other promising drug candidates, OCS-02 and OCS-05, are progressing through Phase 2 development for ocular inflammation and neuroprotection, respectively.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.